- Trials with a EudraCT protocol (260)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
260 result(s) found for: MDD AND Depression AND Major Depressive Disorder.
Displaying page 5 of 13.
EudraCT Number: 2015-005081-30 | Sponsor Protocol Number: 16903A | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patient... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Prematurely Ended) FI (Completed) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005354-20 | Sponsor Protocol Number: 12710A | Start Date*: 2016-03-15 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disor... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) GB (Completed) HU (Completed) BG (Completed) DE (Completed) FI (Not Authorised) IT (Completed) ES (Completed) BE (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003401-87 | Sponsor Protocol Number: SND103285 | Start Date*: 2006-02-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001326-10 | Sponsor Protocol Number: 18315A | Start Date*: 2019-12-26 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, open-label study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder and early dementia | |||||||||||||
Medical condition: Depressive symptoms in patients with major depressive disorder (MDD) and early dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002007-29 | Sponsor Protocol Number: 42165279MDD2001 | Start Date*: 2015-11-24 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di... | |||||||||||||
Medical condition: Major Depressive Disorder Anxiety | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003948-67 | Sponsor Protocol Number: 331-12-282 | Start Date*: 2013-05-08 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization,Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo- and Active Comparator-controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With M... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006540-54 | Sponsor Protocol Number: CL3-20098-063 | Start Date*: 2007-06-11 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multice... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021216-41 | Sponsor Protocol Number: H9P-MC-LNBR(a) | Start Date*: 2011-01-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders... | |||||||||||||
Medical condition: Major depressive disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005424-85 | Sponsor Protocol Number: 3151A1-3360-WW | Start Date*: 2009-07-15 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer company | |||||||||||||
Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Di... | |||||||||||||
Medical condition: The desvenlafaxine succinate sustained release formulation, DVS SR, is being used in development programs for the treatment of major depressive disorder (MDD). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed) FR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011238-84 | Sponsor Protocol Number: CL3-20098-069 | Start Date*: 2009-09-21 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe Major Depressive Disorder. A 6... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BG (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011200-39 | Sponsor Protocol Number: PKI113009 | Start Date*: 2010-01-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared t... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020726-18 | Sponsor Protocol Number: H9P-MC-LNBO | Start Date*: 2011-01-17 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptak... | |||||||||||||
Medical condition: Major depressive disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004169-28 | Sponsor Protocol Number: SC17.02 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA | |||||||||||||
Full Title: Augmentation versus switch: comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression | |||||||||||||
Medical condition: Non-responders with Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003981-13 | Sponsor Protocol Number: CL3-20098-041 | Start Date*: 2004-12-16 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agome... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003074-14 | Sponsor Protocol Number: MYL-1603N-3002 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:MYLAN INC. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr¿ IM versus Placebo IM as an Enhancer Adjunctive to Ant... | |||||||||||||
Medical condition: Major Depression Disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001436-33 | Sponsor Protocol Number: NP25620 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005612-26 | Sponsor Protocol Number: CL3-01574-237 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel gr... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) FI (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004008-19 | Sponsor Protocol Number: CL3-20098-045 | Start Date*: 2005-08-23 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier [...] | |||||||||||||
Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel... | |||||||||||||
Medical condition: Severe Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000341-14 | Sponsor Protocol Number: 42847922MDD3005 | Start Date*: 2020-08-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) LT (Completed) LV (Completed) BE (Completed) BG (Completed) PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002388-95 | Sponsor Protocol Number: CL3-20098-048 | Start Date*: 2005-11-02 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier [...] | |||||||||||||
Full Title: Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose internationa... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DK (Completed) ES (Completed) BE (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
